A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

NCT06060457 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1900

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: mRNA-1345
BIOLOGICAL: Fluzone HD

Sponsor

ModernaTX, Inc.